Evidence map›Paper›PMID 41316177›Full record

ArticleBMC medicine2025

Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors.

Sungho Bea, Krista F Huybrechts, Robert J Glynn, Seanna M Vine, Shruti Belitkar, Brian T Bateman, Katsiaryna Bykov

Abstract read
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sungho BeaDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Krista F HuybrechtsDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Robert J GlynnDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Seanna M VineDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Shruti BelitkarDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Brian T BatemanDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Katsiaryna BykovDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. kbykov@bwh.harvard.edu.

Funding

Novel approaches to identify and quantify the impact of drug-drug interactions in older adults with diabetes, with a focus on multimorbidity and polypharmacyK01AG068365 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI BYKOV, KATSIARYNA · 2021 to 2025
$621k
AHRQ HHS R01 HS027623AHRQ HHS R01HS027623Korea Health Industry Development Institute RS-2023-00273553NIA NIH HHS K01 AG068365NIA NIH HHS K01AG068365
6 · The paper itself

Abstract

backgroundSelective serotonin reuptake inhibitors (SSRIs) are frequently co-prescribed with opioids, increasing the risk of pharmacokinetic and pharmacodynamic interactions. Hydrocodone, a commonly prescribed opioid metabolized by cytochrome (CYP) 2D6 and CYP3A4, may be affected by enzyme inhibition from certain SSRIs. However, it remains unclear whether all SSRIs pose equal overdose risk or if some may be safer options for patients requiring both medications. Thus, we aimed to evaluate comparative risks of opioid overdose among patients initiating SSRIs while on hydrocodone.

methodsThis population-based cohort study utilized US public and commercial health insurance claims data from 2004 to 2022 and included patients who initiated a SSRI (citalopram, escitalopram, fluoxetine, paroxetine, or sertraline) while receiving hydrocodone treatment. The outcome was hospitalization or emergency department visit due to opioid overdose. We balanced baseline covariates via propensity score matching weights. A weighted Cox proportional hazards model compared rates across the five SSRIs.

resultsAmong 1,486,583 patients who initiated an SSRI while on hydrocodone, 403,488 (27.1%) initiated sertraline, 348,484 (23.4%) initiated citalopram, 311,375 (21.0%) initiated escitalopram, 258,957 (17.4%) initiated fluoxetine, and 164,279 (11.1%) initiated paroxetine. During a median on-treatment follow-up of 28 days, 1500 primary endpoints occurred. Weighted hazard ratios (HRs) for opioid overdose, using sertraline as the reference, were 1.21 (95% CI 1.02-1.42) for citalopram, 1.19 (1.00-1.41) for escitalopram, 1.29 (1.09-1.54) for fluoxetine, and 1.17 (0.95-1.43) for paroxetine. Using citalopram as the reference, HRs were 0.99 (0.83-1.17) for escitalopram, 1.07 (0.91-1.27) for fluoxetine, and 0.97 (0.79-1.18) for paroxetine. Relative to escitalopram, HRs were 1.09 (0.92-1.30) for fluoxetine and 0.98 (0.80-1.20) for paroxetine, and relative to fluoxetine, the HR was 0.90 (0.74-1.10) for paroxetine. Comparisons among SSRIs other than sertraline showed similar risks of overdose. Intention-to-treat analysis yielded similar findings, although the associations were attenuated.

conclusionsIn this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline.

Indexed as

Analgesics, OpioidHydrocodoneOpiate OverdoseSelective Serotonin Reuptake InhibitorsAdministrative Claims, HealthcareAdultAgedCitalopramDrug InteractionsEscitalopramFemaleFluoxetineFollow-Up StudiesHumansIntention to Treat AnalysisMaleAnalgesics, OpioidCitalopramEscitalopramFluoxetineHydrocodoneParoxetineSelective Serotonin Reuptake InhibitorsSertralineDrug-drug interactionHydrocodoneOpioid overdosePharmacoepidemiologySelective serotonin reuptake inhibitors

Identifiers

PMID41316177
PMCPMC12664141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.